Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hirsutanol A is a novel sesquiterpene compound isolated from the marine-derived fungus *Chondrostereum* sp. found in the soft coral *Sarcophyton tortuosum*. It exhibits potent antitumor activity by inducing the accumulation of reactive oxygen species (ROS), specifically hydrogen peroxide, through a mitochondrial-independent mechanism. This elevation of ROS leads to the dysfunction of the mitochondrial membrane potential and the release of cytochrome c into the cytosol, which subsequently triggers apoptosis through the activation of the caspase-3 cascade and PARP cleavage. Additionally, hirsutanol A activates the c-Jun N-terminal kinase (JNK) signaling pathway, which appears to function as a negative feedback regulator of ROS levels. Preclinical studies have demonstrated its efficacy in inhibiting growth in various cancer cell lines, including colon (SW620), breast (MDA-MB-231), and hepatocellular carcinoma, as well as in vivo xenograft models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hirsutanol A.